ABB  Vol.4 No.7 C , July 2013
Intrathecal IgG synthesis in relapsing-remitting multiple sclerosis (MS) is decreased by natural human alpha interferon
Abstract: Intrathecal IgG synthesis (IT IgG Syn) is an established biomarker used for the diagnosis of multiple sclerosis (MS). Earlier studies used this biomarker to assess the impact of 2 different synthetic forms of interferon alpha (IFN-α) in chronic progressive MS. Unexpectedly, IT IgG synthesis was increased by this treatment. For the first time, we have assessed this parameter in relapsing-remitting patients to measure the impact of natural IFN-α treatment in a doseranging study in six dosage groups (5, 10, 15, 20, 25, & 30 MIU). We have found that IFN-α normalized IT IgG Synthesis at 12 weeks treatment for all dosage groups. Two weeks after stopping IFN-α results rose slightly. At 52 weeks, 28 weeks after stopping IFN-a results revealed cessation of IT IgG Synthesis in half of the patients (15, 20, 25 MIU weekly). These results reflect different outcomes for relapsing-remitting patients vs. chronic progressive patients. They may, however, reflect differences in the biological properties of the interferon products used. An optimal range of dosage with natural human IFN-α dosage for MS is suggested by the results.
Cite this paper: Sheremata, W. , Sazant, A. , Riesgo, V. and Burns, A. (2013) Intrathecal IgG synthesis in relapsing-remitting multiple sclerosis (MS) is decreased by natural human alpha interferon. Advances in Bioscience and Biotechnology, 4, 1-5. doi: 10.4236/abb.2013.47A3001.

[1]   Tourtellotte, W.W., Staugaitis, S., Walsh, M.J., Shapshack, P., et al. (1985) The basis of intra-blood-brainbarrier IgG synthesis. Annals of Neurology, 17, 21-27. doi:10.1002/ana.410170107

[2]   Polman, C.H., Reingold, S.C., Banwell, B., Clanet, M., et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology, 69, 292-302. doi:10.1002/ana.22366

[3]   Knobler, R. L. S., Panitch, H., Braheny, S. L., Sipe, J. C., et al. (1984) Systemic alpha-interferon therapy of multiple sclerosis. Neurology, 32, 1273-1279. doi:10.1212/WNL.34.10.1273

[4]   Panitch, H.S., Francis, G.S, Hooper, C.J., et al. (1983) Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon. Annals of Neurology, 18, 434-438. doi:10.1002/ana.410180404

[5]   Kastrukoff, L.F., Oger, J.J.-F., Tourtellotte, W.W., Sack, S.L., Berkowitz, J. and Paty D.W. (1991) Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. II. Immunologic evaluation. Neurology, 41, 1936-1941. doi:10.1212/WNL.41.12.1936

[6]   Kinnunen, E., Timonen, T., Pirttila, T., Kalliomaki, P. et al. (1993) Effects of recombinant alpha-2b-interferon in patients with progressive MS. Acta Neurologica Scandinavica, 87, 457-460.

[7]   Sheremata, W.A. and Minagar, A. (2004) Management of Interferon-beta1b (Betaseron) failures with Interferonalfan3 (Alferon). In: Hommes, O. R. and Comi, G., Ed., Early Indicators, Early Treatments, Neuroprotection in Multiple Sclerosi, Topics in Neuroscience, Springer Verlag, Milano, 191-195. doi:10.1007/978-88-470-2117-4_20

[8]   Strander, H., Cantell, H., Carlstrom, G., Jakobsson, P.A. (1973) Clinical and laboratory investigations on man: Systemic administration of potent interferon to man. Journal of the National Cancer Institute, 51, 733-743

[9]   Miro, J., Aguayo, P., Alvarez, C., et al. (1992) Intrathecal immunoglobulin synthesis in multiple sclerosis: Effect of corticosteroids and azathioprine. European Neurology, 32, 349-353. doi:10.1159/000116859

[10]   Milanese, C., Salmaggi, A., La Mantia, I., Campi, A., et al. (1990) Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results. Journal of Neurology, Neurosurgery & Psychiatry, 53, 354-557. doi:10.1136/jnnp.53.7.554

[11]   Villar, L.M., Garcia-Sanchez, M.I., Costa-Frossard, L, Espino, M, et al. (2012) Immunological markers of optimal response to natalizumab in multiple sclerosis. Archives of Neurology, 68, 191-197. doi:10.1001/archneurol.2011.971

[12]   Brandao, C.O., Ruocco. H.H., Santos Farias, A, Oliveira, C., et al. (2005) Cytokines and intrathecal IgG synthesis in multiple sclerosis patients during clinical remission. Arquivos de Neuro-Psiquiatria, 63, 914-919. doi:10.1590/S0004-282X2005000600002

[13]   Ruocco, H.H., Brandao, C.O., Farias, A.S, Oliveira, E.C, et al. (2012) Quantitative MRI and cerebrospinal fluid inflammatory mediators in Brazilian patients with relapsing-remitting multiple sclerosis before and after treatment with immunomodulators: a g longitudinal study. Neuroimmunomodulation, 19, 277-282. doi:10.1159/000335889

[14]   Prineas, J.W., Kwon, E.E., Cho, E.-S., Sharer, L.R., et al. (2001) Immunopathology of secondary-progressive multiple sclerosis. Annals of Neurology, 50, 646-657. doi:10.1002/ana.1255

[15]   Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano E., and Aloisi, F. (2006) Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathology, 14, 164-174.

[16]   Rice, G.P.A., Woelfel, E.L., Talbot, P.J., Braheny, S.L., et al. (1985) Immunological complications in multiple sclerosis patients receiving interferon. Annals of Neurology, 18, 439-442. doi:10.1002/ana.410180405

[17]   Gaits G and Huber C. (1988) The biology of interferon actions. Blut, 56, 193-199. doi:10.1007/BF00320105

[18]   Kastrukoff, L.F., Oger, J.J., Hashimoto, S.L., Sacks. S.L., et al. (1990) Systemic lymphoblastoid interferon therapy in chronic progressive multiple Sclerosis. I. Clinical and MRI evaluation. Neurology, 40, 479-486. doi:10.1212/WNL.40.3_Part_1.479

[19]   Sheremata, W., Harrington, W., Tornes, L., Ortega, M., McCarthy M. (2011) Therapeutic response to human interferon-alpha-n3 but failure with recombinant interferonalpha-2b in HAM.TSP. Multiple Sclerosis, 17, S280.

[20]   Fattovich, G., Giustina, G., Favarato, S. and Ruol A. (1996) A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. Journal of Hepatology, 24, 38-47. doi:10.1016/S0168-8278(96)80184-X